Showing 6471-6480 of 7747 results for "".
- National Foundation for Cancer Research Taps NYC Dermatologist for Board Seathttps://practicaldermatology.com/news/national-foundation-for-cancer-research-taps-dermatologist-for-board-seat/2461065/The National Foundation for Cancer Research (NFCR) has announced that New York dermatologist Dr. Karen Burke and two others will be joining the board. NFCR was founded in 1973 to support cancer research and public education relating to the prevention, early diagnosis, better treatments
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result
- Light Therapy Fast-tracks Healing of Skin Damage from Brachytherapyhttps://practicaldermatology.com/news/light-therapy-fast-tracks-healing-of-skin-damage-from-brachytherapy/2461055/Light therapy may accelerate the healing of skin damage from radiation therapy by up to 50 percent, according to a recent University at Buffalo-led study. Photobiomodulation – a form of low-dose light therapy –lowered the severity of skin damage from radionecrosis, reduced i
- Nevisense Boosts Clinician Confidence in Early Melanoma Diagnosishttps://practicaldermatology.com/news/nevisense-boosts-clinicians-confidence-in-early-melanoma-diagnosis/2461053/Nevisense provides valuable diagnostic guidance for clinicans when evaluating atypical pigmented skin lesions, according to a new study. The Nevisense method uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. In the pilot study,
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://practicaldermatology.com/news/researchers-define-keys-to-recognizing-ocular-rosacea-1/2461052/A number of eye symptoms may be more common in patients with rosacea compared to those without the skin disease, but the presence of conjunctival telangiectases may be the eye symptom most closely associated with rosacea. Findings come from a study in which researchers evaluated the rig
- Phase 3 Data Show Benefit of Dupixent to Reduce Itch in Prurigo Nodularishttps://practicaldermatology.com/news/phase-3-data-show-benefit-of-dupixent-to-reduce-itch-in-prurigo-nodularis/2461044/Dupixent® (dupilumab) from Sanofi and Regeneron significantly reduced itch and skin lesions compared to placebo at 24 weeks in a phase 3 trial in adults with uncontrolled prurigo nodularis. The new data confirm positive results
- Is CBG the Next CBD for Skincare?https://practicaldermatology.com/news/is-cbg-the-next-cbd-for-skincare/2461042/Cannabigerol (CBG) shows antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays and provides similar benefits when applied topically to human skin, according to new research. In a single-blind c
- ODAC and JDD Honor Dr. Joel L. Cohenhttps://practicaldermatology.com/news/odac-and-jdd-honor-dr-joel-l-cohen/2461040/The ODAC Dermatology, Aesthetic & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), honored Joel L. Cohen, MD, with the 2022 Outstanding Leadership in Dermatology Educa
- DecisionDx-SCC Performs Well as a Risk-Stratification Tool in Patients with High-risk SCChttps://practicaldermatology.com/news/decisiondx-scc-performs-well-as-a-risk-stratification-tool-in-patients-with-high-risk-scc/2461039/Castle Biosciences, Inc’s DecisionDx-SCC can provide significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk), a new study shows. The study appears in&nb
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo